利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

13 条记录 (耗时 0.021 秒)

    Enteral formulation: low in fat and containing protein hydrolysates
    1.
    发明授权
    Enteral formulation: low in fat and containing protein hydrolysates 失效
    肠内配方：脂肪含量低，含有蛋白质水解物

    公开(公告)号：US5998363A

    公开(公告)日：1999-12-07

    申请号：US168796

    申请日：1998-10-08

    申请人： R. Armour Forse ,  Stacey J. Bell ,  Peter Burke

    发明人： R. Armour Forse ,  Stacey J. Bell ,  Peter Burke

    IPC分类号： A23L1/29 ,  A23L1/305 ,  A61K38/01 ,  A61K38/00 ,  A61K31/22 ,  A61K31/70 ,  A61K31/715

    CPC分类号： A61K38/012 ,  A23L33/18 ,  A23L33/40 ,  A61K38/018 ,  A23V2002/00

    摘要： An improved enteral formulation that is low in fat and contains protein hydrolysates has been developed. The osmolality of the formulation is controlled to be below 500 mOs/kg H.sub.2 O, preferably about 300 mOs/kg H.sub.2 O. In a preferred embodiment, the formulation contains corn starch to control blood glucose levels. This formulation is particularly useful for treatment of critically ill patients and in minimizing a risk of pulmonary aspiration and/or gastrointestinal dysfunction in such patients.

    摘要翻译： 已经开发了一种脂肪低和含有蛋白质水解产物的改良肠内制剂。 将制剂的重量克分子渗透浓度控制在低于500mOs / kg H 2 O，优选约300mOs / kg H 2 O。 在优选的实施方案中，制剂含有玉米淀粉以控制血糖水平。 该制剂对于危重病人的治疗和使患者肺吸入和/或胃肠功能障碍的风险最小化特别有用。

    Dietary supplement and method for lowering risk of heart disease
    2.
    发明授权
    Dietary supplement and method for lowering risk of heart disease 失效
    膳食补充剂和降低心脏病风险的方法

    公开(公告)号：US06210686B1

    公开(公告)日：2001-04-03

    申请号：US09215353

    申请日：1998-12-18

    申请人： Stacey J. Bell ,  R. Armour Forse ,  Bruce R. Bistrian

    发明人： Stacey J. Bell ,  R. Armour Forse ,  Bruce R. Bistrian

    IPC分类号： A61K31355

    CPC分类号： A61K31/435 ,  A23L33/21 ,  A23L33/40 ,  A23V2002/00 ,  A61K31/355 ,  A61K31/4415 ,  A61K31/495 ,  Y10S514/824 ,  Y10S514/904 ,  Y10S514/948 ,  A61K2300/00 ,  A23V2250/218 ,  A23V2250/7052 ,  A23V2250/706 ,  A23V2250/712 ,  A23V2250/5034 ,  A23V2250/5058

    摘要： Yeast-derived fiber has been demonstrated, as described herein, to effectively improve the serum lipid profile in humans, when provided as a dietary supplement, without some of the disadvantages known to accompany dietary supplementation with oat fiber or psyllium fiber. Described herein are dietary supplements comprising yeast fiber, e.g., &bgr;-glucan or glucomannan, and further comprising folic acid or a salt thereof, vitamin B6, vitamin B12, and vitamin E. The dietary supplements of the invention can further comprise fats, carbohydrates and proteins, for example, and other ingredients added to formulate a food product. Such food products can be in the form, for example, of solid or semi-solid foods, such as food bars, pudding, or spreads. By including folate and vitamin B6, the dietary supplement provides a second benefit of suppressing the level of homocysteine in the blood. A third benefit is provided by the anti-oxidant properties of vitamin E, particularly the effect of preserving low density lipoproteins from oxidation. Further embodiments of the invention are methods for improving the serum lipid profile in a human, methods for lowering risk of heart disease, and methods for improving cardiovascular health in a human, comprising administering to the human a dietary supplement of the invention.

    摘要翻译： 如本文所述，已经证明了酵母衍生的纤维，当作为膳食补充剂提供时，有效地改善了人类的血清脂质谱，而没有已知的与燕麦纤维或欧车前纤维的膳食补充剂相关的一些缺点。 本文描述的是包含酵母纤维例如β-葡聚糖或葡甘露聚糖并且还包含叶酸或其盐，维生素B6，维生素B12和维生素E的膳食补充剂。本发明的膳食补充剂还可以包含脂肪，碳水化合物和 蛋白质，以及其它添加成分配食品的成分。 这样的食品可以是例如固体或半固体食物，例如食物棒，布丁或散布物的形式。 通过包括叶酸和维生素B6，膳食补充剂提供了抑制血液中同型半胱氨酸水平的第二个好处。 维生素E的抗氧化性质，特别是保护低密度脂蛋白氧化的作用提供了第三个益处。 本发明的其它实施方案是用于改善人类血清脂质分布的方法，用于降低心脏病风险的方法，以及改善人类心血管健康的方法，包括向人类施用本发明的膳食补充剂。

    Method of pulsatile drug infusion
    9.
    发明授权
    Method of pulsatile drug infusion 失效
    搏动药物输注方法

    公开(公告)号：US5403590A

    公开(公告)日：1995-04-04

    申请号：US994198

    申请日：1992-12-21

    申请人： R. Armour Forse

    发明人： R. Armour Forse

    IPC分类号： A61K9/00 ,  A61K31/135 ,  A61K9/08

    CPC分类号： A61K9/0002 ,  A61K31/135

    摘要： A method of pulsatile infusion of a drug or other therapeutic agent is described. The pulsatile infusion method minimizes tachyphylaxis, while enabling the target cell, tissue, or organ to benefit from the administered drug or other therapeutic agent. The drug or other therapeutic agent, an agonist or antagonist for a molecule of the receptor system, is administered in a succession of at least two pulses. The pulses have a selected amplitude and duration so that the binding affinity of the receptor system molecule is decreased by a predetermined amount in response to each pulse. This predetermined amount is less than the difference between the maximum binding affinity of the receptor system molecule, when it is not exposed to either the agonist or antagonist, and its minimum binding affinity for the agonist or antagonist, when it is continuously exposed to the agonist or antagonist. The pulses are spaced apart by a selected interpulse period wherein the binding affinity of the receptor system molecule increases to the maximum value.

    摘要翻译： 描述了药物或其它治疗剂的脉动输注方法。 脉冲输注方法可以最大限度地减少病痛，同时使靶细胞，组织或器官能够从施用的药物或其它治疗剂中获益。 药物或其他治疗剂，受体系统分子的激动剂或拮抗剂以连续的至少两个脉冲施用。 脉冲具有选定的幅度和持续时间，使得受体系统分子的结合亲和力响应于每个脉冲减少预定量。 当预定量不受暴露于激动剂或拮抗剂时，受体系分子的最大结合亲和力及其对激动剂或拮抗剂的最小结合亲和力当其连续暴露于激动剂 或拮抗剂。 脉冲间隔开选定的脉冲间隔，其中受体系统分子的结合亲和力增加到最大值。